Evidence map›Paper›PMID 9281613›Full record

ArticleMolecular pharmacology1997

A mutational analysis of residues essential for ligand recognition at the human P2Y1 receptor.

Q Jiang, D Guo, B X Lee, A M Van Rhee, Y C Kim, R A Nicholas, J B Schachter, T K Harden, K A Jacobson

Abstract read
In one paragraph

Article in Molecular pharmacology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 128 citations in OpenAlex.

  1. Article
  2. Article
  3. Physiologic roles of P2 receptors in leukocytes.Journal of leukocyte biology · 2022
    Review
  4. Article
  5. Article
  6. Update of P2Y receptor pharmacology: IUPHAR Review 27.British journal of pharmacology · 2020
    Review
  7. Review
  8. Review
  9. Article
  10. Demystifying P2YJournal of chemical information and modeling · 2017
    Article
  11. Article
  12. The role of purinergic receptors in stem cell differentiation.Computational and structural biotechnology journal · 2015
    Review
  13. Review
  14. Article
  15. Molecular Structure of P2Y Receptors: Mutagenesis, Modeling, and Chemical Probes.Wiley interdisciplinary reviews. Membrane transport and signaling · 2012
    Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Q JiangMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
D Guo
B X Lee
A M Van Rhee
Y C Kim
R A Nicholas
J B Schachter
T K Harden
K A Jacobson
National Institutes of Health · US

Funding

PROSTHETIC GROUPS FOR RADIOLABELING OF FUNCTIONALIZED DRUGS AND PEPTIDESZ01DK031116 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 1991 to 2008
$769k
Intramural NIH HHS Z01 DK031116Intramural NIH HHS Z99 DA999999Intramural NIH HHS Z99 DK999999Intramural NIH HHS Z99 OD999999
6 · The paper itself

Abstract

We conducted a mutational analysis of residues potentially involved in the adenine nucleotide binding pocket of the human P2Y1 receptor. Mutated receptors were expressed in COS-7 cells with an epitope tag that permitted confirmation of expression in the plasma membrane, and agonist-promoted inositol phosphate accumulation was assessed as a measure of receptor activity. Residues in transmembrane helical domains (TMs) 3, 5, 6, and 7 predicted by molecular modeling to be involved in ligand recognition were replaced with alanine and, in some cases, by other amino acids. The potent P2Y1 receptor agonist 2-methylthio-ATP (2-MeSATP) had no activity in cells expressing the R128A, R310A, and S314A mutant receptors, and a markedly reduced potency of 2-MeSATP was observed with the K280A and Q307A mutants. These results suggest that residues on the exofacial side of TM3 and TM7 are critical determinants of the ATP binding pocket. In contrast, there was no change in the potency or maximal effect of 2-MeSATP with the S317A mutant receptor. Alanine replacement of F131, H132, Y136, F226, or H277 resulted in mutant receptors that exhibited a 7-18-fold reduction in potency compared with that observed with the wild-type receptor. These residues thus seem to subserve a less important modulatory role in ligand binding to the P2Y1 receptor. Because changes in the potency of 2-methylthio-ADP and 2-(hexylthio)-AMP paralleled the changes in potency of 2-MeSATP at these mutant receptors, the beta- and gamma-phosphates of the adenine nucleotides seem to be less important than the alpha-phosphate in ligand/P2Y1 receptor interactions. However, T221A and T222A mutant receptors exhibited much larger reductions in triphosphate (89- and 33-fold versus wild-type receptors, respectively) than in diphosphate or monophosphate potency. This result may be indicative of a greater role of these TM5 residues in gamma-phosphate recognition. Taken together, the results suggest that the adenosine and alpha-phosphate moieties of ATP bind to critical residues in TM3 and TM7 on the exofacial side of the human P2Y1 receptor.

Indexed as

Adenosine MonophosphateAmino Acid SequenceAnimalsBinding SitesCOS CellsDNA Mutational AnalysisEnzyme ActivationEnzyme-Linked Immunosorbent AssayHumansInositol PhosphatesLigandsMolecular Sequence DataMutagenesis, Site-DirectedProtein ConformationReceptors, Purinergic P2Receptors, Purinergic P2Y1Adenosine MonophosphateInositol PhosphatesLigandsP2RY1 protein, humanReceptors, Purinergic P2Receptors, Purinergic P2Y1Type C Phospholipases

Identifiers

PMID9281613
PMCPMC3425637
OpenAlexW2096550848

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.